Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, has been...
BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation of...
BERG, a clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the underlying biology of disease, today...
BERG, the clinical stage biopharmaceutical company that uses artificial intelligence (AI) to discover the biology of underlying disease, today...
BERG, a clinical stage biopharmaceutical company that utilizes artificial intelligence (AI) and multi-omics to identify novel biology and disease...
BERG, a biopharmaceutical company that merges biology with technology to map and identify drivers of diseases, today announced the presentation...
BERG, a biopharmaceutical company, that combines biology and technology to discover novel biology underlying disease, today announced four...
BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced four abstracts...
Berg Analytics, a division of BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases,...
BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, yesterday presented findings...
BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the...
BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today presented in a poster...
BERG, LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced that the U.S....
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of 10 abstracts ...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the dosing of the first patient...
BERG, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the U.S. Food and...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, Massachusetts General Hospital (MGH), and...
BERG, a biopharmaceutical company that merges biology with technology, today announced a new research effort with Sanofi Pasteur, the influenza...
BERG, a biopharmaceutical company that merges biology with technology, today announced that the Company was honored with a Partners in Progress Award ...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the completion of clinical...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced two poster presentations showing ...
BERG, a biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced a research collaboration with...
BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced they have entered...
BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced seven poster...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.